3rd Sep 2020 20:34
Oncimmune Holdings PLC - immunodiagnostics company - Notes the publication by PLOS ONE of a study led by Leeds University Academic Unit of Health Economics, supported by NIHR Leeds In Vitro Diagnostics Co-operative, and funded by The National Institute for Health Research's SBRI Healthcare programme, which evaluated the cost-effectiveness of the EarlyCDT Lung blood test in combination with computed tomography, compared to computed tomography surveillance alone in the diagnosis of lung cancer amongst patients with Indeterminate pulmonary nodules. The results of the study demonstrate that at an example cost of GBP70 per test, the EarlyCDT Lung blood test will have a positive impact on the outcomes of those patients observed, and when used alongside computed tomography surveillance, is a cost-effective approach to the management of patients with indeterminate pulmonary nodules. The study calculates the incremental cost-effectiveness ratio to be GBP2,417, substantially below the accepted GBP20,000 per quality adjusted life year threshold set by NICE.
Current stock price: 162.00 pence
Year-to-date change: quadrupled
By Evelina Grecenko; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Oncimmune